Literature DB >> 24058969

Arsenic trioxide combination improves survival in APL.

Susan Mayor.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24058969     DOI: 10.1016/s1470-2045(13)70348-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide.

Authors:  Lingzhi Zhong; Yang Wang; Wenxue Li; Junlian Gu; Xiuying Li; Xiaotong Wang; Zhen Yue; Yan Mu; Jinping Bai; Ronggui Li; Haiying Zhang
Journal:  Mol Cell Biochem       Date:  2014-03-28       Impact factor: 3.396

2.  Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.

Authors:  Haiying Zhang; Xuejin Su; Li Guo; Lingzhi Zhong; Wenxue Li; Zhen Yue; Xiaotong Wang; Yan Mu; Xinna Li; Ronggui Li; Zonggui Wang
Journal:  Int J Med Sci       Date:  2014-10-02       Impact factor: 3.738

3.  Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis.

Authors:  Chaoyun Pan; Dihan Zhu; Jianjiang Zhuo; Limin Li; Dong Wang; Chen-Yu Zhang; Yuan Liu; Ke Zen
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

4.  Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 by Promoting Nuclear Translocation of NFE2L2.

Authors:  Zhen Yue; Lingzhi Zhong; Yan Mou; Xiaotong Wang; Haiying Zhang; Yang Wang; Jianxin Xia; Ronggui Li; Zonggui Wang
Journal:  Int J Med Sci       Date:  2015-08-01       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.